Harel Insurance Investments & Financial Services Ltd. Alnylam Pharmaceuticals, Inc. Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.8 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 27, 2021	SELL	$126.83 - $175.69 $118,332 - $163,918	-933 Closed	0 $0
Q3 2020 Oct 20, 2020	BUY	$121.19 - $165.49 $113,070 - $154,402	933 New	933 $136,000
Q1 2020 Apr 28, 2020	SELL	$93.12 - $133.99 $53,264 - $76,642	-572 Closed	0 $0
Q4 2019 Jan 23, 2020	BUY	$74.51 - $124.23 $32,784 - $54,661	440 Added 333.33%	572 $66,000
Q2 2019 Jul 22, 2019	SELL	$65.86 - $92.79 $131,720 - $185,580	-2,000 Reduced 93.81%	132 $10,000
Q1 2019 Apr 18, 2019	SELL	$72.76 - $93.45 $13,460 - $17,288	-185 Reduced 7.98%	2,132 $210,000
Q4 2018 Jan 29, 2019	BUY	$62.67 - $88.33 $2,444 - $3,444	39 Added 1.71%	2,317 $169,000
Q3 2018 Oct 29, 2018	BUY	$87.52 - $122.67 $170,926 - $239,574	1,953 Added 600.92%	2,278 $200,000
Q1 2018 Apr 30, 2018	SELL	$115.92 - $148.54 $11,012 - $14,111	-95 Reduced 22.62%	325 $39,000
Q4 2017 Feb 01, 2018	BUY	$114.49 - $139.98 $26,332 - $32,195	230 Added 121.05%	420 $53,000
Q3 2017 Nov 02, 2017	BUY	$72.53 - $118.27 $13,780 - $22,471	190	190 $22,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.2 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.21 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.43 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.26 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account